Classification, differential diagnosis and treatment of diffuse interstitial pulmonary diseases are considered. Data on their X-ray (computed tomographic) and morphological manifestations are presented along with analysis of efficiency of pathogenetic (anti-inflammatory and antifibrotic) therapy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

diffuse interstitial
8
interstitial pulmonary
8
[differential diagnosis
4
diagnosis diffuse
4
pulmonary diseases]
4
diseases] classification
4
classification differential
4
differential diagnosis
4
diagnosis treatment
4
treatment diffuse
4

Similar Publications

Background: The risk factors for interstitial lung disease (ILD) in rheumatoid arthritis (RA) are inconsistent among previous studies. Furthermore, the factors associated with the emergence of the recently defined progressive fibrosing (PF) phenotype are unknown. Herein, we analyze the risk factors for ILD in RA.

View Article and Find Full Text PDF

Fluid flow and amyloid transport and aggregation in the brain interstitial space.

PNAS Nexus

January 2025

Université Paris Cité, CNRS, Laboratoire de Biochimie  Théorique, 13 rue Pierre et Marie Curie, Paris 75005, France.

The driving mechanisms at the base of the clearance of biological wastes in the brain interstitial space (ISS) are still poorly understood and an actively debated subject. A complete comprehension of the processes that lead to the aggregation of amyloid proteins in such environment, hallmark of the onset and progression of Alzheimer's disease, is of crucial relevance. Here we employ combined computational fluid dynamics and molecular dynamics techniques to uncover the role of fluid flow and proteins transport in the brain ISS.

View Article and Find Full Text PDF

A spontaneous pneumothorax may be the heralding manifestation of diffuse cystic lung disease (DCLD). Historically, these diagnoses were differentiated by unique clinical, radiographic and tissue pathology characteristics. With recent advancements in genomics, several forms of DCLD can now be diagnosed through genetic testing and patients can thereby avoid undergoing an invasive lung biopsy.

View Article and Find Full Text PDF

Circulating MicroRNAs in Idiopathic Pulmonary Fibrosis: A Narrative Review.

Curr Issues Mol Biol

December 2024

Molecular Biology Laboratory, Department of Research in Pulmonary Fibrosis, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Mexico City 14080, Mexico.

Idiopathic pulmonary fibrosis (IPF) is a chronic, deathly disease with no recognized effective cure as yet. Furthermore, its diagnosis and differentiation from other diffuse interstitial diseases remain a challenge. Circulating miRNAs have been measured in IPF and have proven to be an adequate option as biomarkers for this disease.

View Article and Find Full Text PDF

Objectives: To investigate the impact of the different proportions of crescent formation on clinical manifestations and pathological features in children with immunoglobulin A vasculitis with nephritis (IgAVN).

Methods: The children with IgAVN were divided into no-crescent group (75 children), ≤25% crescent group (156 children), and >25% crescent group (33 children).

Results: Compared with the no-crescent group, the other two groups had significant increases in 24-hour urinary protein, urinary immunoglobulin G (IgG)/creatinine ratio, urine red blood cell count, fibrinogen, and neutrophil-lymphocyte ratio, a significant reduction in serum IgG, and a significantly higher proportion of children with low albumin and hypercoagulability, pathological grade III+IV or diffuse mesangial proliferation (<0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!